Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results

Open Access

Peer-reviewed

Research Article

Judy M. Bradley,

Affiliation Institute of Nursing and Health Research, University of Ulster, Ulster, Northern Ireland
⨯
Paul Koker,

Affiliation Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States of America
⨯
Qiqi Deng,

Affiliation Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States of America
⨯
Petra Moroni-Zentgraf,

Affiliation Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
⨯
Felix Ratjen,

Affiliation The Hospital for Sick Children, Toronto, Ontario, Canada
⨯
David E. Geller,

Affiliation Florida State University College of Medicine, Orlando, Florida, United States of America
⨯
J. Stuart Elborn ,

* E-mail: s.elborn@qub.ac.uk

Affiliation Centre for Infection and Immunity, Queen’s University Belfast, Belfast, Northern Ireland
⨯
on behalf of the Tiotropium Cystic Fibrosis Study Group

Reader Comments (0)

Cystic fibrosis
Is the Subject Area "Cystic fibrosis" applicable to this article?

Thanks for your feedback.
Receptor antagonist therapy
Is the Subject Area "Receptor antagonist therapy" applicable to this article?

Thanks for your feedback.
Pulmonary function
Is the Subject Area "Pulmonary function" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Bronchodilators
Is the Subject Area "Bronchodilators" applicable to this article?

Thanks for your feedback.
Age groups
Is the Subject Area "Age groups" applicable to this article?

Thanks for your feedback.
Antibiotics
Is the Subject Area "Antibiotics" applicable to this article?

Thanks for your feedback.
Inhalation
Is the Subject Area "Inhalation" applicable to this article?

Thanks for your feedback.